drugset
drugset / Trial / NCT05875493

A Food Effect Study of JAB-21822 in Healthy Subjects

NCT05875493 ↗

Phase 1 Completed 18 enrolled Allist Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective of this study is to determine the effect of food in healthy participants on the bioavailability of JAB-21822 following single dose administration with and without a meal

Timeline

Start
2023-05-12
Primary completion
2023-06-14
Completion
2023-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Glecirasib Small molecule — Oral

Indications

No indication recorded.